Immuron (IMRN) vs Senti Biosciences (SNTI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Senti Biosciences is the larger company by market cap ($9.8 million vs $8.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMRN | SNTI |
|---|---|---|
| Share price | $1.08 | $0.3144 |
| Market cap | $8.72M | $9.79M |
| 1-day change | -2.70% | -2.27% |
| YTD return | — | -69.07% |
| 1-year return | — | -81.93% |
| 5-year return | — | -99.68% |
| EPS (TTM) | $-0.34 | $-1.72 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.39 | $2.88 |
| 52-week low | $0.677 | $0.29 |
| Distance from 52-week high | -54.81% | -89.08% |
| Analyst consensus | none | none |
| Avg. price target upside | +260.19% | +4193.89% |
| Average volume | 2.06M | 573.78K |
| Shares outstanding | 8.07M | 31.15M |
| Employees | 7 | 39 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Immuron
IMRN stock →Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About Senti Biosciences
SNTI stock →Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company's lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 39 employees
IMRN vs SNTI FAQ
Which is bigger, Immuron or Senti Biosciences?
Senti Biosciences (SNTI) is larger, with a market capitalization of $9.79M compared with $8.72M for Immuron (IMRN).
Are Immuron and Senti Biosciences in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Immuron and Biotechnology: Biological Products (No Diagnostic Substances) for Senti Biosciences.